UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Nature communications, 2016-08, Vol.7 (1), p.12335-12335, Article 12335

2016

Volltextzugriff (PDF)

Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway

Cell reports (Cambridge), 2017-04, Vol.19 (2), p.375-388

2017

Volltextzugriff (PDF)

Characterization of the novel HLA‐B35:08:17 allele

HLA, 2024-02, Vol.103 (2), p.e15365-n/a

2024

Volltextzugriff (PDF)

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Oncoimmunology, 2021-01, Vol.10 (1), p.1943253

2021

Volltextzugriff (PDF)

Cooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic Mice

Neoplasia (New York, N.Y.), 2011-03, Vol.13 (3), p.254-IN12

2011

Volltextzugriff (PDF)

Preliminary Assessment of Legacy and Current-Use Pesticides in Franciscana Dolphins from Argentina

Bulletin of environmental contamination and toxicology, 2018-07, Vol.101 (1), p.14-19

2018

Volltextzugriff (PDF)

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Science translational medicine, 2020-06, Vol.12 (548)

2020

Volltextzugriff (PDF)

COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer

Oncogene, 2018-08, Vol.37 (34), p.4735-4749

2018

Volltextzugriff (PDF)

Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model

Cancer biology & therapy, 2013-04, Vol.14 (4), p.357-364

2013

Volltextzugriff (PDF)

Antitumor Activity of Tumor-Targeted RNA Replicase-Based Plasmid That Expresses Interleukin‑2 in a Murine Melanoma Model

Molecular pharmaceutics, 2013-06, Vol.10 (6), p.2404-2415

2013

Volltextzugriff (PDF)

Characterization and Comparison of GITR Expression in Solid Tumors

Clinical cancer research, 2019-11, Vol.25 (21), p.6501-6510

2019

Volltextzugriff (PDF)

COX-2 mediates pro-tumorigenic effects of PKC[epsilon] in prostate cancer

Oncogene, 2018-08, Vol.37 (34), p.4735

2018

Volltextzugriff (PDF)

Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.488-488

2021

Volltextzugriff (PDF)

Immune analysis of fibrolamellar hepatocellular carcinoma

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.324-324

2017

Volltextzugriff (PDF)

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.52-52

2019

Volltextzugriff (PDF)

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.185-185

2019

Volltextzugriff (PDF)

Abstract 5423: Diet induced obesity, inflammation and prostate cancer progression in Hi-Myc mice

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5423-5423

2012

Volltextzugriff (PDF)

Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3604-3604

2019

Volltextzugriff (PDF)

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4599-4599

2020

Volltextzugriff (PDF)

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.486-486

2020

Volltextzugriff (PDF)

Prognostic implications of TAMs in colorectal cancer hepatic metastases

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3574-3574

2017

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(143)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway

Characterization of the novel HLA‐B35:08:17 allele

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Cooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic Mice

Preliminary Assessment of Legacy and Current-Use Pesticides in Franciscana Dolphins from Argentina

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer

Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Entrepôts et trafics annonaires en Méditerranée

Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model

Antitumor Activity of Tumor-Targeted RNA Replicase-Based Plasmid That Expresses Interleukin‑2 in a Murine Melanoma Model

Characterization and Comparison of GITR Expression in Solid Tumors

COX-2 mediates pro-tumorigenic effects of PKC[epsilon] in prostate cancer

Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer

Immune analysis of fibrolamellar hepatocellular carcinoma

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Abstract 5423: Diet induced obesity, inflammation and prostate cancer progression in Hi-Myc mice

Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts)

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Prognostic implications of TAMs in colorectal cancer hepatic metastases

Suchergebnisse filtern